Abstract. miR‑574‑5p has been reported involved in the pathogenesis of numerous human malignancies such as colorectal and lung cancer. In this study, we aimed to explore the roles of REL and miR‑574 in the recurrence of prostate cancer (PCa) and to identify the underlying molecular mechanisms. Our literature search found that miR‑574 is regulated in cancer stem cells (CSCs), and next we used the microRNA (miRNA) database (www.mirdb.org) to find REL as a target of miR‑574. Luciferase assay was performed to verify the miRNA/target relationship. Oligo‑transfection, real‑time PCR and western blot analysis were used to support the conclusions. We validated REL to be the direct gene via luciferase reporter assay system, and real‑time PCR and western blot analysis were also conducted to study the mRNA and protein expression level of REL between different groups (recurrence and non‑recurrence) or cells treated with scramble control, miR‑574 mimics, REL siRNA and miR‑574 inhibitors, indicating the negative regulatory relationship between miR‑574 and REL. We also investigated the relative viability of prostate CSCs when transfected with scramble control, miR‑574 mimics, REL siRNA and miR‑574 inhibitors to validate miR‑574 to be positively interfering with the viability of prostate CSCs. We then investigated the relative apoptosis of prostate CSCs when transfected with scramble control, miR‑574 mimics, REL siRNA and miR‑574 inhibitors. The results showed miR‑574 inhibited apoptosis. In conclusion, miR‑574 might be a novel prognostic and therapeutic target in the management of PCa recurrence.

Introduction

Prostate cancer (PCa), which is a heterogeneous‑multifocal disease, ranks the most common cancer in men (1). The PCa incidence is growing, particularly in developed countries. One in six males in America will suffer from PCa in their lifetime, and every year there are >900,000 newly diagnosed PCa cases in the world (2). Genetic and environmental factors have been reported to be involved in the control of carcinogenesis and progression of PCa (3).

Over the past decades, recurrence of PCa, which often demonstrates chemotherapy‑resistant and androgen‑independence, has drawn increasing attention. Great efforts have been made and considerable progress has been achieved to understand the molecular mechanism of the disease including epithelial‑mesenchymal transition (EMT) (4), multidrug resistance gene expression (5), the mutation or amplification of androgen receptor and cancer stem cells (CSCs) or CSC‑like cells (6). CSC model was first verified in acute myeloid leukemia (AML) in 1997 (7,8). This model supposed that cancers possessed hierarchical organization as the normal tissues did to a large degree and a small subset of tumor cells which were characterized by remarkable ability to generate new tumors constituted CSCs. Subsequently, CSCs have been identified in numerous human malignancies, including PCa, liver cancer, pancreatic cancer, brain cancer and breast cancer (9‑13). Consequently, it is important to identify the novel markers of CSCs, as more effective therapies might be available for patients with cancers.

As small non‑coding RNAs consisting of 18‑22 nucleotides, microRNAs (miRNAs) serve as important regulators in post‑transcriptional regulation of target genes and mRNA silence by binding to the 3'‑untranslated region (3'UTR), leading to inhibition or degradation of targeted miRNAs (14). Some miRNAs have been confirmed to be involved in numerous biological processes (15,16). miRNAs have been shown to be involved in the control of recurrence of PCa (17), and have also been reported to be involved in regulating characteristics of CSCs (18). It has been previously shown that miR‑574 is substantially downregulated in CSCs (19), and REL is believed to be a significant regulator of cancer cell proliferation (20). In this study, we confirmed the regulatory relationship between miR‑574 and REL and verified that miR‑574/REL signaling pathway is involved in the control of recurrence of PCa by modulating the expression of REL.
Materials and methods

Study population and sample collection. In this study, we collected PCa samples with recurrence (n=24) and without recurrence (n=24) from Dongying People’s Hospital of Shandong. Patients with a prostate-specific antigen (PSA) elevation of >0.2 ng/ml after initially receiving radical prostatectomy (RP) or radiotherapy with curative intent is defined as biochemical recurrence. The study protocol was approved by the Ethics Committee of Dongying People's Hospital of Shandong. Written informed consents were obtained from all patients prior to the study.

Western blot analysis. Proteins were extracted from the cells using 1X Radioimmunoprecipitation Assay (RIPA) Lysis buffer (Upstate Biotechnology, Lake Placid, NY, USA) and the protein level was determined using protein assay reagents according to standard protocols (Bio-Rad Laboratories, Hercules, CA, USA). Western blot analysis was performed to assess protein expression. Briefly, 25 µg of total protein was loaded on Life Technologies NuPAGE® 4-12% Bis-Tris gel (Thermo Fisher Scientific) and electrophoresed. After transferring to a pure nitrocellulose membrane (Bio-Rad Laboratories), we blocked the membranes with Odyssey® blocking buffer (LI-COR Biosciences, Lincoln, NE, USA). The membranes were then incubated in primary antibodies buffer (Odyssey blocking buffer, 0.1% Tween-20®) overnight at 4°C. The primary antibodies, anti-REL and anti-actin, were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). The following day, membranes were washed four times for 5 min in Tris-buffered saline and Tween-20 (TBST). Subsequently, membranes were incubated in secondary antibodies IRDye® 680LT goat anti-mouse IgG or anti-rabbit IgG (Cell Signaling Technology, Inc.) plus Odyssey blocking buffer and 0.1% Tween-20 at 1:20,000 dilution for 1 h.

RNA isolation and real-time PCR. We extracted total RNA from PC-3 cells or tissue samples using High Pure Isolation kit in accordance with the manufacturer's instructions (Roche Life Science, West Sussex, UK). The miRNA Q-PCR detection kit (GeneCopoeia) was employed to quantify miR-574 level according to the manufacturer’s instructions. Briefly, the protocol was conducted for 35 cycles at 95°C for 5 min, 95°C for 10 sec, and 55°C for 10 sec. In total, 50 cycles were performed. The PCR amplification for the quantification of the miR-574 or REL and U6 was performed using TaqMan miRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. Primer sets for miR-574 or REL were designed using Primer3 software version 1.0 (Whitehead Institute for Biomedical Research, Cambridge, MA, USA). All the reactions were performed in triplicate and data were expressed as 2-ΔΔCt.

Luciferase assay. The 3’UTR segment of miR-574 and REL siRNA was amplified and subcloned into the pmirGLO luciferase reporter vector (Promega). The corresponding mutant constructs were generated by mutating the seed regions of the miR-574 or REL siRNA binding sites. The cells (3.5x10⁴) were seeded in triplicate in 24-well plates and cotransfected with wild-type (Wt)/mutant (Mt) 3’UTR vectors and miR-574 mimics or scramble control using Lipofectamine 2000. After 48 h of transfection, the cells were measured for luciferase activity on the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. The firefly luciferase activities were normalized to Renilla luciferase activity. All experiments were repeated three times.

Cell proliferation assay. The viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The cells were seeded at a density of 2x10⁵ cells/well in 96-well culture plates and incubated for 24 h at 37°C prior to transfection. The following day, cells were transfected with miR-574 or REL siRNA. After 48 h, 20 ml of MTT solution (5 mg/ml in PBS) was added to each well. Samples were further incubated for 4 h. The absorbance was read on a SPECTRANax® microplate spectrophotometer ( Molecular Devices, LLC, Sunnyvale, CA, USA) at a wavelength of 490 nm. Experiments were carried out in triplicates.

CSC culture and transfection. Tumorsphere (prostasphere) was cultured as described previously (18). Resulting tumorspheres were maintained at least 2 weeks with medium being changed at a 3-day interval. These prostaspheres cultures contained mainly cells with stemness markers and were considered as CSCs. miR-574 or REL siRNA mimics and scramble control mimics (GenePharma, Suzhou, China) were transfected in CSCs at a concentration of 50 nM with Lipofectamine 2000 reagent (Invitrogen).

Apoptosis analysis. PC-3 cells were seeded in 6-well plates (3.5×10⁵ cells/well) and transfected with mimics or inhibitors of miR-574 or NC as a control. Twenty-four hours later, 50 nmol/l of paclitaxel was added in media. After 48 h of incubation, cells were harvested and washed with cold PBS, stained with 5 µl Annexin V-FITC and 10 µl propidium iodide (PI) (20 µg/ml). The mixture was incubated at room temperature in the dark for 15 min. Cell apoptosis was analyzed on the FACScan flow cytometer (Becton Dickinson, USA). Each experiment with triplicate samples was repeated three times.

Statistical analysis. The target genes of specific miRNAs were predicted using two prediction algorithms, TargetScan (http://www.targetscan.org/) and miRDB (http://mirdb.org/cgi-bin/search.cgi). The t-test (two groups) or one-way ANOVA (three groups or more) was used for assessing the statistical significance of each differential expression analysis result. All statistical analysis was performed using SPSS 20.0 (IBM, Inc., Chicago, IL, USA). P<0.05 was considered significant.

Results

REL is the virtual target of miR-574-5p. miR-574-5p has been reported involved with many diseases such as colorectal cancer, liver metastasis and lung cancer. In order to understand the role of miR-574-5p in PCa recurrence, we used online miRNA target prediction tools to search the regulatory gene of miR-574-5p, and consequently identified CCNG2, CUL5, EZH1 and REL as the candidate target genes of miR-574-5p in prostate CSCs with the ‘seed sequence’ in the 3’UTR (Fig. 1).
Furthermore, to validate the regulatory relationship among miR-574-5p and CCNG2, CUL5, EZH1 and REL, we also conducted luciferase activity reporter assay in prostate CSCs, we can see the luciferase activity from the cells cotransfected with miR-574-5p and wild-type REL 3'UTR decrease significantly (Fig. 2), while cells cotransfected with miR-574-5p and CCNG2, CUL5, EZH1 3'UTR were comparable with scramble control (Fig. 2). The results confirmed that REL was a validated target of miR-574-5p in prostate CSCs. To further investigate the modulatory relationship between miR-574-5p and REL, we then analyzed the correlation between the expression level of miR-574-5p and REL mRNA among the tissues (n=48), they showed negative regulatory relationship (Fig. 3).

**Determination of expression patterns of miR-574 and REL in tissues with different groups.** The tissues of two different groups (recurrence, n=24; non-recurrence, n=24) were used to further explore the impact on the interaction between miR-574 and REL 3'UTR. Using real-time PCR, we found that the expression of miR-574 decreased in recurrence groups (Fig. 4A) compared with non-recurrence group while the expression of REL mRNA (Fig. 4B) increased in the recurrence group compared with non-recurrence group; the expression of REL protein (Fig. C) was measured by densitometry analysis and we found it increased in the recurrence group compared with the normal group. To further validate the hypothesis of the negative regulatory relationship between miR-574-5p and REL, we investigated the mRNA/protein expression level of REL of prostate CSCs, by transfection with the prostate CSCs with scramble control, miR-574 mimics, REL siRNA and miR-574 inhibitors. As shown in Fig. 5, the REL protein (upper panel) and mRNA expression level (lower panel) of prostate CSCs treated with miR-574 mimics and REL siRNA were apparently lower than the scramble control, while cells treated miR-574 inhibitors were higher than the scramble control, validating the negative regulatory relationship between miR-574-5p and REL.

**miR-574 and REL interfere with the viability in prostate CSCs.** We also investigated the relative viability of prostate CSCs when transfected with scramble control, miR-574 mimics, REL siRNA and miR-574 inhibitors. Cells transfected with miR-574 inhibitors showed evident downregulated viability (Fig. 6A) when compared with the scramble controls, while cells transfected with miR-574 mimics and REL siRNA showed comparably lower viability, indicating miR-574 positively interfered with the viability of prostate CSCs, while REL negatively interfered with the viability of prostate CSCs.

**miR-574 and REL interfere with apoptosis in prostate CSCs.** We then investigated the relative apoptosis of prostate CSCs when transfected with scramble control, miR-574 mimics, REL siRNA and miR-574 inhibitors. When transfected with miR-574 mimics and REL siRNA, the number of surviving cells were more and the number of apoptotic cells were...
less than the scramble controls, while cells transfected with miR-574 inhibitors showed comparably less survival cells and more apoptotic cells. The results indicated that miR-574 inhibited apoptosis and REL accelerated apoptosis.

**Discussion**

CSCs have been proven to be present in numerous malignancies and it is believed that they are related to cancer recurrence, metastasis and resistance to chemo/radiotherapy (21). CSCs in PCa ranking the most common cancer in men worldwide have been identified (22). Several features of PCa CSCs such as metastatic potential, functional characteristics, gene expression profiles and molecular signatures have been reported (23). Most data on CSCs were achieved from PCa cell lines, mainly from animal models and metastasis where the main bias was generated, leading to clinical objection of the findings. Some molecular markers for CSC including $\alpha_2\beta_1$ integrin and Cd40, CD44, and CD133 were identified by the above research (24).

In this study, we found that the expression of miR-574 decreased in recurrence groups (Fig. 4A) compared with non-recurrence group while the expression of REL mRNA (Fig. 4B) increased in recurrence group compared with non-recurrence group; the expression of REL protein (Fig. 4C) was measured by densitometry analysis and we found that it increased in recurrence group compared with normal group.

Previous functional study indicated that overexpression of miR-574 led to inhibition of the invasion, migration, proliferation ability of gastric cancer cells (25). Downregulation of miR-574 in gastric cancer might be related to progression and development (25). Moreover, recent research considered that miR-574 served as tumor suppressor in bladder cancer (26). miRNAs exert a biological function by inducing target mRNA degradation, consequently, each miRNA can inhibit the production of a number of proteins (27). It is known that miR-574 suppressed the invasion, migration, proliferation ability and induced apoptosis of BC cells by targeting mRNAs of mesoderm development candidate 1 (MESDC1) directly (26). However, it remains unclear whether miR-574-3p...
exhibits the suppressive effect by targeting CUL2 directly in gastric cancer cells, which need further research to be proven. In this study, we conducted luciferase activity reporter assay in PCa cells, and found that the luciferase activity from the cells cotransfected with miR-574-5p and wild-type REL 3'UTR decreased significantly (Fig. 2), and then we analyzed the correlation between the expression level of miR-574-5p and REL mRNA in the tissues (n=48), the results showed negative regulatory relationship (Fig. 3). The results confirmed that REL was a validated target of miR-574 in prostate CSCs, and miR-574 might be a novel prognostic and therapeutic target in the management of PCa recurrence.

Taken together, the findings indicated that REL is a direct target of miR-574 in prostate CSCs, and miR-574 might be a novel prognostic and therapeutic target in the management of PCa recurrence.

References


